Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Lung adenocarcinoma
ADR ID BADD_A07369
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.19      Respiratory and mediastinal neoplasms malignant and unspecified
16.19.01      Non-small cell neoplasms malignant of the respiratory tract cell type specified
16.19.01.002      Lung adenocarcinoma
22      Respiratory, thoracic and mediastinal disorders
22.08      Respiratory tract neoplasms
22.08.01      Lower respiratory tract neoplasms
22.08.01.007      Lung adenocarcinoma
Description A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer. [MeSH]
MedDRA Code 10025031
MeSH ID D000077192
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Adenocarcinoma lung | Adenocarcinoma of lung | Adenocarcinoma of lung stage unspecified | Lung adenocarcinoma | Lung adenocarcinoma NOS | Lung adenocarcinoma metastatic | Adenocarcinoma of Lung | Lung Adenocarcinomas | Lung Adenocarcinoma | Adenocarcinoma, Lung | Adenocarcinomas, Lung
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D02257Trametinib0.000224%
BADD_D02344Vemurafenib0.000112%
BADD_D02345Venetoclax0.000112%
BADD_D02375Water--
BADD_D02392Zoledronic acid0.004294%
BADD_D02443Tiotropium0.000115%
BADD_D02464Fingolimod0.000964%
BADD_D02470Nintedanib0.000224%
BADD_D02480Alectinib0.000280%
BADD_D02509Brigatinib0.000336%
BADD_D02540Capmatinib0.000168%
BADD_D02573Mobocertinib0.000168%
BADD_D02596Sotorasib0.000336%
The 2th Page    First    Pre   2    Total 2 Pages